In addition, ES2 (a peptide that can interfere with the FOXO4-P53 signaling pathway and induce apoptosis) is a senolytic product that specifically eliminates senescent cancer cells, delays tumor growth, and improves survival outcomes when combined with prosenescence agents [73]. Here, TP53 is linked to cancer.